T1	Participants 62 151	patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin
T2	Participants 216 249	patients with chronic hepatitis C
T3	Participants 462 563	treatment-naive patients with HCV genotype 1 infection enrolled in a large expanded access programme.
T4	Participants 572 688	Eight hundred and ninety-one patients treated for 48 weeks with an initial ribavirin dose of 800 or 1000/1200 mg/day
T5	Participants 1555 1574	genotype 1 patients
